Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
onatasertib
- Development stage
- Phase 2
- Lead developer
- Antengene
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Onatasertib is an orally available, selective dual inhibitor of the mammalian target of rapamycin (mTOR) kinase complexes mTORC1 and mTORC2. It is a small molecule antineoplastic agent developed for the treatment of various cancers. By inhibiting both mTORC1 and mTORC2, onatasertib disrupts key signaling pathways involved in tumor cell growth, proliferation, and survival, leading to induction of apoptosis and decreased tumor cell proliferation. Preclinical studies have shown that it can also disrupt mitochondrial function and induce reactive oxygen species production. Onatasertib has been investigated in clinical trials for multiple myeloma, non-Hodgkin's lymphoma (including diffuse large B-cell lymphoma), solid tumors (including liver cancer and non-small cell lung cancer), glioblastoma multiforme, hepatocellular carcinoma, cervical cancer, nasopharyngeal carcinoma, ovarian carcinoma, among others[1][2][3][4][5][6].
- Brand names
- onatasertib
- Other names
- onatasertibATG 008ATG008ATG-008CC-223CC223CC 223
02
Targets
Mechanistic target of rapamycin complex 1Mechanistic target of rapamycin kinase complex 2
Beyond the preview
Go deeper on onatasertib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on onatasertib.